Recent advance in carbohydrate-based cancer vaccines.
- Author:
Chang-Xin HUO
1
;
Xin-Shan YE
Author Information
1. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, Tumor-Associated, Carbohydrate;
chemistry;
immunology;
Cancer Vaccines;
chemical synthesis;
chemistry;
immunology;
therapeutic use;
Carbohydrates;
chemistry;
immunology;
Epitopes, T-Lymphocyte;
chemistry;
immunology;
Glycoconjugates;
chemistry;
immunology;
Humans;
Immune Tolerance;
Metabolic Engineering;
methods;
Neoplasms;
prevention & control;
therapy;
Oligosaccharides;
chemistry
- From:
Acta Pharmaceutica Sinica
2012;47(3):261-270
- CountryChina
- Language:Chinese
-
Abstract:
The abnormal glycans expressing on the surface of tumor cells are good targets to develop carbohydrate-based anti-cancer vaccines. However, one of the major problems is that carbohydrate antigens possess weak immunogenicity. This review summarizes the recent efforts to overcome this problem: glycoconjugates produced by coupling the carbohydrate antigens and proper carrier proteins improve their immunogenicity, many glycoconjugates have entered clinical trials; the vaccines become chemically well-defined when coupling the carbohydrate antigens with a T-cell peptide epitope and an immunostimulant to form fully synthetic multi-component glycoconjugate vaccines; the modification of carbohydrate antigens in combination with the technology of metabolic oligosaccharide engineering of tumor cells induces a strong immune response; and the fact that the antibodies elicited against the unnatural carbohydrate antigens can recognize the native carbohydrate antigens on tumor cells provides a new promising strategy for the development of anti-cancer vaccines.
